Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2342
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers ; volume:16 ; number:1 ; day:5 ; month:5 ; year:2016 ; pages:1-9 ; date:12.2016
BMC medical imaging ; 16, Heft 1 (5.5.2016), 1-9, 12.2016
- Creator
-
Stoppino, Luca Pio
- Contributor
-
Della Valle, Nicola
Rizzi, Stefania
Cleopazzo, Elsa
Centola, Annarita
Iamele, Donatello
Bristogiannis, Christos
Stoppino, Giuseppe
Vinci, Roberta
Macarini, Luca
SpringerLink (Online service)
- DOI
-
10.1186/s12880-016-0139-7
- URN
-
urn:nbn:de:1111-201605068558
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Stoppino, Luca Pio
- Della Valle, Nicola
- Rizzi, Stefania
- Cleopazzo, Elsa
- Centola, Annarita
- Iamele, Donatello
- Bristogiannis, Christos
- Stoppino, Giuseppe
- Vinci, Roberta
- Macarini, Luca
- SpringerLink (Online service)
Other Objects (12)
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn’s Disease (CD)
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn’s Disease (CD)
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn’s Disease (CD)
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease